Maxwellia Poised To Become Consumer Health Player If Daily Contraceptive Switch Approved

Maxwellia is ready to market its Lovima daily contraceptive as a non-prescription brand if its application to switch the progestogen-only pill (POP) in the UK is approved, representing a leap forward for the company. CEO Anna Maxwell tells HBW Insight about Maxwellia's journey from R&D start-up to consumer health player.